Kodiak Sciences (KOD) Consolidated Net Income (2017 - 2026)
Kodiak Sciences (KOD) reported Consolidated Net Income of -$58.1 million for Q1 2026, down 1.16% on a YoY basis from -$58.8 million in Q1 2025, and down 2.54% quarter-over-quarter from -$56.7 million in Q4 2025.
Kodiak Sciences (KOD) Consolidated Net Income (2017 - 2026) Analysis & Trends
Kodiak Sciences has reported Consolidated Net Income for 10 years, with the latest figure at -$58.1 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 1.16% year-over-year to -$58.1 million; the trailing twelve-month figure through Mar 2026 stood at -$230.5 million (down 21.04% YoY), and the FY2025 full-year result was -$229.9 million, down 30.83% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$58.1 million, down from -$56.7 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$42.7 million in Q1 2024, with the low at -$95.7 million in Q1 2022.
- Historically, Consolidated Net Income has averaged -$62.3 million across 5 years, with a median of -$58.1 million in 2026.
- Annual changes were most pronounced in 2022 — Consolidated Net Income sank 89.82% — and 2024, when it soared 43.82%.
- Kodiak Sciences' Consolidated Net Income stood at -$71.1 million in 2022, then climbed by 16.29% to -$59.5 million in 2023, then grew by 25.94% to -$44.0 million in 2024, then slipped by 28.71% to -$56.7 million in 2025, then fell by 2.54% to -$58.1 million in 2026.
- The last three Consolidated Net Income figures came in at -$58.1 million (Q1 2026), -$56.7 million (Q4 2025), and -$61.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Kodiak Sciences | 1.92 Bn | 1.92 Bn | - | -58.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.14 Mn |
| Dec 31, 2025 | -56.70 Mn |
| Sep 30, 2025 | -61.44 Mn |
| Jun 30, 2025 | -54.27 Mn |
| Mar 31, 2025 | -57.47 Mn |
| Dec 31, 2024 | -44.05 Mn |
| Sep 30, 2024 | -43.92 Mn |
| Jun 30, 2024 | -45.03 Mn |
| Mar 31, 2024 | -42.70 Mn |
| Dec 31, 2023 | -59.48 Mn |
| Sep 30, 2023 | -49.97 Mn |
| Jun 30, 2023 | -80.15 Mn |
| Mar 31, 2023 | -71.00 Mn |
| Dec 31, 2022 | -71.05 Mn |
| Sep 30, 2022 | -77.00 Mn |
| Jun 30, 2022 | -90.58 Mn |
| Mar 31, 2022 | -95.70 Mn |
| Dec 31, 2021 | -93.05 Mn |
| Sep 30, 2021 | -67.50 Mn |
| Jun 30, 2021 | -55.83 Mn |